FDA Grants Priority Review for WINREVAIR Label Update Based on ZENITH Trial
FDA Grants Priority Review to Merck’s WINREVAIR™ Based on Landmark ZENITH Trial Showing Dramatic Reduction in Morbidity and Mortality in PAH Patients Merck (NYSE: MRK), operating as MSD outside the…
Gilead Advances in HIV Market With Twice-Yearly Yeztugo, Leaving GSK Behind
Gilead Targets HIV Prevention Dominance With Twice-Yearly Yeztugo as GSK Mounts a Defense Gilead Sciences is taking a bold step to further entrench itself as the dominant force in HIV…
Lupin Unveils New Consumer Healthcare Arm: LupinLife
Lupin Launches LupinLife as Independent Subsidiary to Strengthen Focus on India’s Self-Care Market Global pharmaceutical leader Lupin Limited has announced a significant strategic move to bolster its consumer healthcare operations.…
WHO-backed testing model boosts mpox, HIV, and syphilis response
As mpox cases surge once again in parts of Central Africa, the Democratic Republic of the Congo (DRC) is leading a bold, innovative strategy by integrating HIV and syphilis testing…
Suriname Officially Certified Malaria-Free by WHO
Suriname Becomes First Amazon Nation to Earn WHO Malaria-Free Certification In a historic public health milestone, the Republic of Suriname has been officially certified as malaria-free by the World Health…
Jazz Pharma Gets EU Nod for Ziihera in Advanced HER2+ Biliary Cancer
Jazz Pharmaceuticals Secures Conditional EU Approval for Ziihera® (zanidatamab) to Treat Advanced HER2-Positive Biliary Tract Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that the European Commission (EC) has granted…
WuXi Biologics Unveils WuXiHigh™ 2.0 for Ultra-Concentrated Biologics
WuXi Biologics Launches WuXiHigh™ 2.0 to Advance High-Concentration Biologic Formulations WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the official launch of WuXiHigh™…
BioMarin Completes Acquisition of Inozyme Pharma
BioMarin Finalizes Acquisition of Inozyme Pharma, Strengthening Rare Disease Portfolio with INZ-701 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has officially completed the acquisition of Inozyme Pharma, Inc. (Nasdaq: INZY), a move…
Genmab Unveils Executive Committee Restructuring
Genmab Announces Leadership Transition as Chief Legal Officer Birgitte Stephensen Retires, Greg Mueller Appointed Successor Genmab A/S (Nasdaq: GMAB), a leading international biotechnology company focused on antibody-based therapeutics for cancer…
argenx Advances ARGX-119 for Congenital Myasthenic Syndromes
argenx Advances ARGX-119 into Registrational Study for Congenital Myasthenic Syndromes Following Positive Phase 1b Data argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving outcomes for…
Biogen Launches Phase 3 Trial of Felzartamab for Primary Membranous Nephropathy
Biogen Launches Global Phase 3 PROMINENT Trial Evaluating Felzartamab in Primary Membranous Nephropathy Biogen Inc. (Nasdaq: BIIB) has announced the initiation of dosing in its global Phase 3 clinical trial,…
Takeda’s GAMMAGARD LIQUID ERC Approved by FDA as First Ready-to-Use Low-IgA Immunoglobulin Therapy
Takeda Secures FDA Approval for GAMMAGARD LIQUID ERC, the First Ready-to-Use Liquid Immunoglobulin Therapy with Low IgA Content Takeda (TSE:4502/NYSE:TAK) announced today that the U.S. Food and Drug Administration (FDA)…